



## **Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference**

August 27, 2025

CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York.

A live webcast of the fireside chat will be available [here](#) and in the investors section of the company's website at [www.designtx.com](http://www.designtx.com). The webcast will be archived for at least 30 days following the presentation.

### **About Design Therapeutics**

Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC<sup>®</sup> gene targeted chimera small molecules. The company's GeneTAC<sup>®</sup> molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC<sup>®</sup> programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington's disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit [designtx.com](http://designtx.com).

### **Contact:**

Renee Leck  
THRUST Strategic Communications  
[renee@thrustsc.com](mailto:renee@thrustsc.com)